US20120283466A1 - Lacosamide intermediate compound, preparation method thereof and use thereof - Google Patents

Lacosamide intermediate compound, preparation method thereof and use thereof Download PDF

Info

Publication number
US20120283466A1
US20120283466A1 US13/519,902 US201213519902A US2012283466A1 US 20120283466 A1 US20120283466 A1 US 20120283466A1 US 201213519902 A US201213519902 A US 201213519902A US 2012283466 A1 US2012283466 A1 US 2012283466A1
Authority
US
United States
Prior art keywords
benzyl
tert
formula
acetyl
benzyloxycarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/519,902
Inventor
Xianyi ZHANG
Shaoqing GE
Daqing Che
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Original Assignee
Zhejiang Jiuzhou Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Jiuzhou Pharmaceutical Co Ltd filed Critical Zhejiang Jiuzhou Pharmaceutical Co Ltd
Assigned to ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. reassignment ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHE, DAQING, GE, SHAOQING, ZHANG, XIANYI
Publication of US20120283466A1 publication Critical patent/US20120283466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Definitions

  • the present invention relates to the field of organic chemistry and medical chemistry, in particular, to an intermediate compound of medication lacosamide, and a preparation method thereof and a use thereof.
  • Lacosamide chemical name: (R)—N-benzyl-2-acetamido-3-methoxypropionamide, CAS number: 175481-36-4, has a structural formula shown below:
  • Lacosamide is a medication for treating epilepsy and neuropathic pain developed by Schwarz biosciences in Germany, and is used for the adjunctive treatment of partial-onset epilepsy in 16 years old or older patients with or without secondary generalized seizures.
  • Lacosamide also referred to as erlosamide, has an action mode different from that of all the current commercially available antiepileptic drugs: lacosamide regulates the activity of sodium channels, while other commercially available antiepileptic drugs block the sodium channels.
  • the sodium channels play a vital role in adjustment of nervous system activity for nerve cell communication. Sometimes, abnormal hyperactivity of the sodium channel may cause seizures of epilepsy.
  • the action mode of lacosamide is considered as to reduce the hyperactivity of the sodium channels, and the motion of adjusting nerve cells may control the seizures of epilepsy.
  • Clinical studies also indicate that, lacosamide is bound to collapse response mediator protein-2 (CRMP-2, mainly distributed in phosphoprotein in the nervous system for neurounal differentiation and for controlling axonal overgrowth), and lacosamide is the unique antiepileptic drug on the market that interacts with CRMP-2.
  • CRMP-2 collapse response mediator protein-2
  • group -Cbz specifically is benzyloxycarbonyl, that is,
  • Route two and Route one lies in that, Compound 1 is subjected to an alkylation reaction; next. Compound 6 is subjected to a condensation reaction, to obtain Compound 3, it can be found through comparison with Route one that, the order of the alkylation reaction and the condensation reaction is reverse.
  • the common features of the two routes are that: reagents and methods used in the alkylation reaction and the condensation reaction are substantially the same; during the reactions, a benzyloxycarbonyl group is used to protect the amino group, so a process of protection of the benzyloxycarbonyl group and a process of deprotection of the benzyloxycarbonyl group are involved, and the methods corresponding to the two steps are the same; and finally, the methods for preparing lacosamide from Compound 4 are the same. Therefore, it can be seen that, during the preparation of lacosamide, the order of the alkylation reaction and the condensation reaction and the step and method for protecting the amino group are very important.
  • the present invention is directed to a new compound, which is used for preparing lacosamide.
  • the present invention is also directed to a method for preparing the new compound.
  • the present invention is also directed to a novel method for preparing lacosamide.
  • the new compound according to the present invention has a structural formula represented by Formula (I):
  • R1 may be benzyloxycarbonyl (Cbz), 9-fluorenemethoxycarbonyl (Fomc), 2-biphenylyl-2-propoxycarbonyl (BRoc), phthalimidyl, p-tosyl, trifluoroacetyl, formyl (—HCO), acetyl (CH 3 CO—), benzoyl (PhCO—), benzyl, allyl, dialkyl phosphoryl, tert-butoxycarbonyl (Boa or a C 1 -C 20 aliphatic alkoxycarbonyl; R2 may be hydrogen, hydroxyl, a C 1 -C 20 aliphatic hydrocarbyl, or an aromatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl; and when R2 is hydrogen, R1 is not benzyloxycarbonyl.
  • Cbz
  • R1 is benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), or ethoxycarbonyl (CH 3 CH 2 O(O)C—).
  • a more preferred compound represented by Formula (I) according to the present invention specifically is:
  • R1 is 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, ally, dialkyl phosphoryl, tert-butoxycarbonyl, or a C 1 -C 10 aliphatic alkoxycarbonyl.
  • the compound represented by Formula (I-1) may be prepared from a compound represented by Formula (II) ((R)-2-amino-N-benzyl-3-hydroxypropionamide) and a compound represented by R1-R3, and the specific reaction is shown below:
  • R1 is defined as in the compound represented by Formula (I); and R3 may be a halogen (such as F, Cl Br, or I), with chloride being preferred; and
  • R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl, dialkylphosphoryl, tert-butoxycarbonyl, or a C 1 -C 20 aliphatic alkoxycarbonyl; R2 is a C 1 -C 20 aliphatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl.
  • the compound represented by Formula (I-2) may be prepared by the compound represented by Formula (I-1) through an alkylation reaction, and the specific reaction is shown below:
  • R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl dialkyl phosphoryl, tert-butoxycarbonyl, or a C 1 -C 20 aliphatic alkoxycarbonyl; R2 is a C 1 -C 20 aliphatic hydrocarbyl; and when R1 is benzyloxycarbonyl, acetyl, or tert-butoxycarbonyl. R2 is not methyl.
  • the alkylating agent for the alkylation reaction is preferably dimethyl sulfate;
  • the reactant (I-1) is preferably (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide;
  • the prepared compound represented by Formula, (I-2) is preferably (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide.
  • a method for preparing the compound represented by Formula (II) includes: condensating (R)-2-(tert-butoxyamino)-3-hydroxylpropionic acid (Compound (IV)) and benzylamine to obtain (R)—N-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide (Compound (III)); and deprotecting Compound (III) to obtain (R)-2-amino-N-benzyl-3-hydroxypropionamide (Compound (II)).
  • the specific reaction formulas are shown below:
  • the acid 1 may be an inorganic acid or trifluoroacetic acid; and preferably hydrochloric acid.
  • the base 1 may be an inorganic base; and preferably sodium hydroxide or potassium hydroxide.
  • the compound represented by Formula (I) may be used to prepare a compound represented by Formula (V) and medication lacosamide, that is, Compound (I) is deprotected to obtain the compound represented by Formula (V); Compound (V) reacts with acetyl chloride to obtain lacosamide. Furthermore, the specific reaction formulas are shown below:
  • R1 and R2 are defined as in the compound represented by Formula (I); and R1 is preferably ethoxycarbonyl, and R2 is preferably methyl.
  • the acid 2 may be an inorganic acid or trifluoroacetic acid; and preferably hydrochloric acid.
  • the base 2 may be an inorganic base; and preferably sodium hydroxide or potassium hydroxide.
  • the present invention has the following beneficial effects.
  • a new compound is provided, which can be used to prepare lacosamide; and a novel method for preparing lacosamide is also provided.
  • iodomethane and silver oxide that are cost expensive are not used, nor a Pd—C catalyst is used, so the production cost is low, the raw materials and accessory materials are cheap and easily available, and the process is simple, so that industrial production is easy to realize; and moreover, the yield is high, and good economic efficiency can be achieved.
  • the formulated benzyl amine-ethyl acetate solution (32.16 g benzyl amine dissolved in 150 g anhydrous ethyl acetate) was added at ⁇ 1) to ⁇ 10° C. Then, the temperature was raised to 10-15° C., and reaction was performed at this temperature. After reaction, 200 g tap water was added, and the mixture was stirred for several minutes, and stood for layering. An organic layer was separated, and washed with 200 g dilute hydrochloric acid and 200 g saturated aqueous solution of sodium chloride. The solvent was evaporated, to obtain a colorless transparent oily substance, which was triturated with petroleum ether and suction-filtered.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A new compound is provided, which is used for preparing lacosamide. A novel method for preparing lacosamide is also provided. During the reaction, iodomethane and silver oxide that are cost expensive are not used, nor a Pd-c catalyst is used, so the production cost is low, the raw materials and accessory materials are cheap and easily available, and the process is simple, so that industrial production is easy to realize; and moreover, the yield is high, and good economic efficiency can be achieved.
Figure US20120283466A1-20121108-C00001

Description

  • This application is a 35 USC 111 continuation of PCT/CN2011/070737 filed Jan. 28, 2011, which claims priority to Chinese Patent Application No, 291010198504.7, filed with the Chinese Patent Office on Feb. 6, 2010 and entitled “LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF”, which is incorporated herein by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to the field of organic chemistry and medical chemistry, in particular, to an intermediate compound of medication lacosamide, and a preparation method thereof and a use thereof.
    • BACKGROUND OF THE INVENTION
  • Lacosamide, chemical name: (R)—N-benzyl-2-acetamido-3-methoxypropionamide, CAS number: 175481-36-4, has a structural formula shown below:
  • Figure US20120283466A1-20121108-C00002
  • Lacosamide is a medication for treating epilepsy and neuropathic pain developed by Schwarz biosciences in Germany, and is used for the adjunctive treatment of partial-onset epilepsy in 16 years old or older patients with or without secondary generalized seizures. Lacosamide, also referred to as erlosamide, has an action mode different from that of all the current commercially available antiepileptic drugs: lacosamide regulates the activity of sodium channels, while other commercially available antiepileptic drugs block the sodium channels. The sodium channels play a vital role in adjustment of nervous system activity for nerve cell communication. Sometimes, abnormal hyperactivity of the sodium channel may cause seizures of epilepsy. Therefore, the action mode of lacosamide is considered as to reduce the hyperactivity of the sodium channels, and the motion of adjusting nerve cells may control the seizures of epilepsy. Clinical studies also indicate that, lacosamide is bound to collapse response mediator protein-2 (CRMP-2, mainly distributed in phosphoprotein in the nervous system for neurounal differentiation and for controlling axonal overgrowth), and lacosamide is the unique antiepileptic drug on the market that interacts with CRMP-2.
  • In U.S. Pat. No. 6,048,899 (patentee: Research Corporation Tech., Inc., publication date: Apr. 11, 2000), Lacosamide is first reported, and the preparation process is shown below:
  • Figure US20120283466A1-20121108-C00003
  • where the group -Cbz specifically is benzyloxycarbonyl, that is,
  • Figure US20120283466A1-20121108-C00004
  • Note: the group -Cbz in the following structures and specifications are as defined above.
  • In this route, two critical intermediates, that is, Compound 2 and Compound 3 are involved:
  • Figure US20120283466A1-20121108-C00005
  • In the preparation of lacosamide through the reactions mentioned above, iodomethane and silver oxide that are cost expensive need to be used, which is not beneficial to industrial production; and moreover, in deprotection of the group Cbz, a Pd—C catalyst is used, and the production cost is high.
  • In U.S. Pat. No. 6,048,899, another route, that is, Route two, is disclosed:
  • Figure US20120283466A1-20121108-C00006
  • The difference between Route two and Route one lies in that, Compound 1 is subjected to an alkylation reaction; next. Compound 6 is subjected to a condensation reaction, to obtain Compound 3, it can be found through comparison with Route one that, the order of the alkylation reaction and the condensation reaction is reverse. The common features of the two routes are that: reagents and methods used in the alkylation reaction and the condensation reaction are substantially the same; during the reactions, a benzyloxycarbonyl group is used to protect the amino group, so a process of protection of the benzyloxycarbonyl group and a process of deprotection of the benzyloxycarbonyl group are involved, and the methods corresponding to the two steps are the same; and finally, the methods for preparing lacosamide from Compound 4 are the same. Therefore, it can be seen that, during the preparation of lacosamide, the order of the alkylation reaction and the condensation reaction and the step and method for protecting the amino group are very important.
    • DESCRIPTION OF THE INVENTION
  • The present invention is directed to a new compound, which is used for preparing lacosamide.
  • The present invention is also directed to a method for preparing the new compound.
  • The present invention is also directed to a novel method for preparing lacosamide.
  • The new compound according to the present invention has a structural formula represented by Formula (I):
  • Figure US20120283466A1-20121108-C00007
  • where R1 may be benzyloxycarbonyl (Cbz), 9-fluorenemethoxycarbonyl (Fomc), 2-biphenylyl-2-propoxycarbonyl (BRoc), phthalimidyl, p-tosyl, trifluoroacetyl, formyl (—HCO), acetyl (CH3CO—), benzoyl (PhCO—), benzyl, allyl, dialkyl phosphoryl, tert-butoxycarbonyl (Boa or a C1-C20 aliphatic alkoxycarbonyl; R2 may be hydrogen, hydroxyl, a C1-C20 aliphatic hydrocarbyl, or an aromatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl; and when R2 is hydrogen, R1 is not benzyloxycarbonyl.
  • In a preferred compound represented by Formula (I) according to the present invention. R1 is benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), or ethoxycarbonyl (CH3CH2O(O)C—).
  • A more preferred compound represented by Formula (I) according to the present invention specifically is:
    • (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide; and
    • (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide.
  • In the compound represented by Formula (I), when R2 is hydrogen, the structure is shown by Formula (I-1):
  • Figure US20120283466A1-20121108-C00008
  • where R1 is 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, ally, dialkyl phosphoryl, tert-butoxycarbonyl, or a C1-C10 aliphatic alkoxycarbonyl.
  • The compound represented by Formula (I-1) may be prepared from a compound represented by Formula (II) ((R)-2-amino-N-benzyl-3-hydroxypropionamide) and a compound represented by R1-R3, and the specific reaction is shown below:
  • Figure US20120283466A1-20121108-C00009
  • where R1 is defined as in the compound represented by Formula (I); and R3 may be a halogen (such as F, Cl Br, or I), with chloride being preferred; and
      • moreover, Compound R1-R3 is preferably ethyl chlorocarbonate; and the prepared compound represented by Formula (I-1) is preferably (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide.
  • In the compound represented by Formula (II), when R2 is a C1-C20 aliphatic hydrocarbyl, the structural formula is as shown in Formula (I-2):
  • Figure US20120283466A1-20121108-C00010
  • where R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl, dialkylphosphoryl, tert-butoxycarbonyl, or a C1-C20 aliphatic alkoxycarbonyl; R2 is a C1-C20 aliphatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl.
  • The compound represented by Formula (I-2) may be prepared by the compound represented by Formula (I-1) through an alkylation reaction, and the specific reaction is shown below:
  • Method a:
  • Figure US20120283466A1-20121108-C00011
  • Method b:
  • Figure US20120283466A1-20121108-C00012
  • In the above two reactions. R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl dialkyl phosphoryl, tert-butoxycarbonyl, or a C1-C20 aliphatic alkoxycarbonyl; R2 is a C1-C20 aliphatic hydrocarbyl; and when R1 is benzyloxycarbonyl, acetyl, or tert-butoxycarbonyl. R2 is not methyl.
  • Furthermore, the alkylating agent for the alkylation reaction is preferably dimethyl sulfate; the reactant (I-1) is preferably (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide; the prepared compound represented by Formula, (I-2) is preferably (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide.
  • A method for preparing the compound represented by Formula (II) includes: condensating (R)-2-(tert-butoxyamino)-3-hydroxylpropionic acid (Compound (IV)) and benzylamine to obtain (R)—N-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide (Compound (III)); and deprotecting Compound (III) to obtain (R)-2-amino-N-benzyl-3-hydroxypropionamide (Compound (II)). Furthermore, the specific reaction formulas are shown below:
  • Figure US20120283466A1-20121108-C00013
  • Furthermore, the acid 1 may be an inorganic acid or trifluoroacetic acid; and preferably hydrochloric acid.
  • Furthermore, the base 1 may be an inorganic base; and preferably sodium hydroxide or potassium hydroxide.
  • The compound represented by Formula (I) may be used to prepare a compound represented by Formula (V) and medication lacosamide, that is, Compound (I) is deprotected to obtain the compound represented by Formula (V); Compound (V) reacts with acetyl chloride to obtain lacosamide. Furthermore, the specific reaction formulas are shown below:
  • Figure US20120283466A1-20121108-C00014
  • where R1 and R2 are defined as in the compound represented by Formula (I); and R1 is preferably ethoxycarbonyl, and R2 is preferably methyl.
  • Furthermore, the acid 2 may be an inorganic acid or trifluoroacetic acid; and preferably hydrochloric acid.
  • Furthermore, the base 2 may be an inorganic base; and preferably sodium hydroxide or potassium hydroxide.
  • The present invention has the following beneficial effects. A new compound is provided, which can be used to prepare lacosamide; and a novel method for preparing lacosamide is also provided. During the reactions, iodomethane and silver oxide that are cost expensive are not used, nor a Pd—C catalyst is used, so the production cost is low, the raw materials and accessory materials are cheap and easily available, and the process is simple, so that industrial production is easy to realize; and moreover, the yield is high, and good economic efficiency can be achieved.
    • EMBODIMENTS
  • Hereinafter, the present invention is described with reference to the following embodiments.
    • Embodiment 1 Preparation of (R)—N-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide
  • Figure US20120283466A1-20121108-C00015
  • 32.16 g (0.30 mol) benzyl amine was dissolved in 150 g anhydrous ethyl acetate to formulate a solution for use.
  • To a 1000 mL four-Deck round bottom flask, 51.5 g (0.25 mol) (R)-2-(tert-butoxyamino)-3-hydroxypropionic acid and 450 g anhydrous ethyl acetate were added in sequence, and mechanical stirring was started. The temperature was decreased to −10° C., 27.83 g (0.275 mol) N-methylmorpholine and 37.59 g (0.275 mol) isobutyl chloroformate were added into the system. After addition, the formulated benzyl amine-ethyl acetate solution (32.16 g benzyl amine dissolved in 150 g anhydrous ethyl acetate) was added at −1) to −10° C. Then, the temperature was raised to 10-15° C., and reaction was performed at this temperature. After reaction, 200 g tap water was added, and the mixture was stirred for several minutes, and stood for layering. An organic layer was separated, and washed with 200 g dilute hydrochloric acid and 200 g saturated aqueous solution of sodium chloride. The solvent was evaporated, to obtain a colorless transparent oily substance, which was triturated with petroleum ether and suction-filtered. A filter cake was leached with a suitable amount of petroleum ether, and then dried in an oven. Finally, 53.0 g (0.180 mol) target product was obtained. The molar yield was 71.86%, and the HPLC purity was 94.84%. The product can be directly used in a following reaction without further purification.
    • Embodiment 2 Preparation of (R)-2-amino-N-benzyl-3-hydroxypropionamide
  • Figure US20120283466A1-20121108-C00016
  • To a 500 mL four-neck round bottom flask, 34.0 g (R)—N-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide and 350 mL dichloromethane were added, and the mixture was stirred to obtain a clear solution. At 20-25° C., 40.0 g concentrated hydrochloric acid (having a mass concentration of 36.0%) was added, and the reaction was continued. TLC tracking was performed, till the raw materials were completely converted. After the reaction was completed, the temperature was decreased to 20° C. The mixture was suction-filtered, to obtain a white needle-like crystal. The obtained white crystalline solid was dissolved in 50 g water. At 20-25° C., 30% sodium hydroxide solution was added to adjust the pH value of the system to 8-9. After the addition, the solution was stirred continuously, and a white flaky crystal was precipitated. The mixture was suction-filtered, and the filter was washed and dried, to obtain a target product of 16.5 g (0.085 mol). The molar yield was 73.52%.
    • Embodiment 3 Preparation of (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide
  • Figure US20120283466A1-20121108-C00017
  • To a 250 mL three-neck round bottom flask, 9.65 g (0.0497 mol) (R)-2-amino-N-benzyl-3-hydroxypropionamide, 120 mL tetrahydrofuran, and 7.58 g (0.0749 mol) triethylamine were added in sequence, the mixture was stirred to obtain a solution. At a normal temperature, 6.01 g (0.0554 mol) ethyl chlorocarbonate was added. After the reaction was completed, the solvent was evaporated, and the residue was added with 100 mL water, and stirred uniformly. The solution was extracted with 50 mL×3 ethyl acetate, and the organic phases were combined and dried over anhydrous sodium sulfate. The solvent was evaporated, to obtain a white solid of 9.67 g (0.0363 mol). The molar yield was 73.04%.
    • Embodiment 4 Preparation of (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide
  • Figure US20120283466A1-20121108-C00018
  • To a 500 mL three-neck round bottom flask 7.2 g (0.027 mol) (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide, 300 mL ethyl acetate, 27.2 g (0.216 mol) dimethyl sulfate, and 2.0 g tetrabutylammonium bromide were added in sequence. At a normal temperature, 24.8 g 50% potassium hydroxide (0.2214 mol) solution was added. After the reaction was completed, 100 mL water was added, and the mixture was stirred for several minutes, and stood for layering. An organic layer was separated, and washed with a saturated sodium chloride aqueous solution and dried over anhydrous sodium sulfate. The solvent was evaporated, to obtain a transparent oily substance, which was triturated with n-hexane, suction-filtered, washed, and dried, to obtain a white solid of 5.37 g (0.01916 mol). The molar yield was 70.96%.
    • Embodiment 5 Preparation of (R)-2-amino-N-benzyl-3-methoxypropionamide
  • Figure US20120283466A1-20121108-C00019
  • To a 100 mL single-neck flask, 5.6 g (0.02 mol) (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide and 50 mL 31% concentrated hydrochloric acid were added, the mixture was heated and refluxed for 6-10 hr. After the reaction as completed, 30% sodium hydroxide solution was added to adjust the pH value of the system to 8-9. The reaction liquid was extracted with 50 mL×2 dichloromethane, and dried over anhydrous sodium sulfate. The product can be directly used in following synthesis without further purification.
    • Embodiment 6 Preparation of (R)-2-acetylamino-N-benzyl-3-methoxypropionamide
  • Figure US20120283466A1-20121108-C00020
  • To a 100 mL three-neck round bottom flask, the organic obtained in Embodiment 5 and 2.22 g (0.022 mol) triethylamine were added, and the temperature was decreased to 10° C. At 10-25° C., 1.73 g (0.022 mol) acetyl chloride was added slowly. After addition, the reaction was continued, till the raw materials were completely converted. After the reaction was completed, the reaction liquid was washed with 40 g×2 saturated sodium bicarbonate solution. The solvent was evaporated, to obtain 3.92 g white solid. The product was recrystallized with an n-hexane-ethyl acetate mixture solvent, to obtain a white powder solid of 3.12 g (0.0125 mol). The molar yield was 62.4% (with respect to (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide).
  • The above description is merely preferred embodiments of the present invention. It should be noted that, persons of ordinary skill in the in can make several improvements and modifications without departing from the principle of the present invention, and the improvements and modifications should also be construed as falling within the protection scope of the present invention.

Claims (11)

1. A compound represented by Formula (I):
Figure US20120283466A1-20121108-C00021
wherein R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl, dialkyl phosphoryl, tert-butoxycarbonyl, or a C1-C20 aliphatic alkoxycarbonyl; R2 is hydrogen, hydroxyl, a C1-C20 aliphatic hydrocarbyl or an aromatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl; and when R2 is hydrogen, R1 is not benzyloxycarbonyl.
2. The compound according to claim 1, wherein the structural formula is shown in Formula (I-1):
Figure US20120283466A1-20121108-C00022
wherein R1 is 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl, dialkyl phosphoryl, tert-butoxycarbonyl, or a C1-C20 aliphatic alkoxycarbonyl.
3. The compound according to claim 1, wherein the structural formula is shown in Formula (I-2):
Figure US20120283466A1-20121108-C00023
wherein R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl, dialkyl phosphoryl, tert-butoxycarbonyl, or a C1-C20 aliphatic alkoxycarbonyl; R2 is a C1-C20 aliphatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl.
4. The compound according to claim 1, specifically being (R)—N-benzyl-2-(ethoxycarbonylamino)-3-hydroxypropionamide or (R)—N-benzyl-2-(ethoxycarbonylamino)-3-methoxypropionamide.
5. A method for preparing the compound according to claim 2, wherein a compound represented by Formula (II) and a compound represented by R1-R3 are used:
Figure US20120283466A1-20121108-C00024
wherein R1 is defined as in claims 2; and R3 is a halogen.
6. A method for preparing the compound according to claim 3, comprising a step of an alkylation reaction of a compound represented by Formula (I-1) and
Figure US20120283466A1-20121108-C00025
wherein R1 is benzyloxycarbonyl, 9-fluorenemethoxycarbonyl, 2-biphenylyl-2-propoxycarbonyl, phthalimidyl, p-tosyl, trifluoroacetyl, formyl, acetyl, benzoyl, benzyl, allyl, dialkyl phosphoryl, tert-butoxycarbonyl, or a C1-C20 aliphatic alkoxycarbonyl; R2 is a C1-C20 aliphatic hydrocarbyl; and when R2 is methyl, R1 is not acetyl, benzyloxycarbonyl, or tert-butoxycarbonyl.
7. The preparation method according to claim 6, wherein an alkylating agent for the alkylation reaction is dimethyl sulfate.
8. A method for preparing lacosamide, comprising:
Step 1: deprotecting the compound according to claim 1, to obtain a compound represented by Formula (V):
Figure US20120283466A1-20121108-C00026
wherein R1 and R2 are as defined in claim 1;
Step 2: reacting the compound of Formula (V) with acetyl chloride, to prepare lacosamide.
9. The preparation method according to claim 8, wherein the deprotection reaction is performed in the presence of trifluoroacetic acid or an inorganic acid with hydrochloric acid being preferred or an inorganic base with potassium hydroxide or sodium hydroxide being preferred.
10. A method for preparing (R)-2-amino-N-benzyl-3-hydroxypropionamide, comprising:
condensating (R)-2-(tert-butoxyamino)-3-hydroxylpropionic acid and benzylamine to obtain (R)—N-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide, and deprotecting (R)—N-benzyl-2-(tert-butoxycarbonylamino)-3-hydroxypropionamide to obtain (R)-2-amino-N-benzyl-3-hydroxypropionamide.
11. The preparation method according to claim 10, wherein the deprotection reaction is performed in the presence of trifluoroacetic acid or an inorganic acid with hydrochloric acid being preferred or an inorganic base with potassium hydroxide or sodium hydroxide being preferred.
US13/519,902 2010-02-06 2012-06-29 Lacosamide intermediate compound, preparation method thereof and use thereof Abandoned US20120283466A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201001085047 2010-02-06
CN20100108504.7 2010-02-06

Publications (1)

Publication Number Publication Date
US20120283466A1 true US20120283466A1 (en) 2012-11-08

Family

ID=47090670

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/579,065 Expired - Fee Related US8829226B2 (en) 2010-02-06 2011-01-28 Lacosamide intermediate compound, preparation method thereof and use thereof
US13/519,902 Abandoned US20120283466A1 (en) 2010-02-06 2012-06-29 Lacosamide intermediate compound, preparation method thereof and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/579,065 Expired - Fee Related US8829226B2 (en) 2010-02-06 2011-01-28 Lacosamide intermediate compound, preparation method thereof and use thereof

Country Status (1)

Country Link
US (2) US8829226B2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130350A1 (en) * 2004-10-02 2011-06-02 Ucb Pharma Gmbh Synthesis scheme for lacosamide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048899A (en) 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
EP2262764B1 (en) 2008-04-01 2014-11-12 The University of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110130350A1 (en) * 2004-10-02 2011-06-02 Ucb Pharma Gmbh Synthesis scheme for lacosamide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cocinero et al, J of American Chemical Soc, 2009, 131(3), 1282-1287( RN 929294-59-7) *

Also Published As

Publication number Publication date
US8829226B2 (en) 2014-09-09
US20130066102A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
US8008479B2 (en) Organic compounds
US8058432B2 (en) Method for preparing phenylalanine derivatives having quinazoline-dione skeleton and intermediates for use in the preparation of derivatives
US20060058548A1 (en) Process of preparing O-carbamoyl compounds in the presence of active amine group
US8907132B2 (en) Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide
US8981095B2 (en) Intermediate compounds and process for the preparation of lurasidone and salts thereof
US20100222586A1 (en) Methods for Producing Sulfonic Acid Diamides
US10544434B2 (en) Process for the preparation of lisdexamfetamine and related derivatives
WO2014116012A1 (en) Method for preparing amicarbazone
CN106397273A (en) Improved preparation method of sacubitril intermediate
US11198684B2 (en) Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same
WO2011095110A1 (en) Intermediate compounds of lacosamide, preparation methods and uses thereof
US20090088571A1 (en) Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides
US20120283466A1 (en) Lacosamide intermediate compound, preparation method thereof and use thereof
US20050222450A1 (en) Process for preparing carbamates
EP1586552B1 (en) Process for producing benzylamine derivative
US8093384B2 (en) Processes for the preparation of alfuzosin
US20100267755A1 (en) Pyrimidine derivatives
US9540344B2 (en) Production method for isoquinoline derivatives and salts thereof
US6538160B2 (en) Process for producing α-aminohalomethyl ketone derivatives
JPS6321659B2 (en)
US20070249627A1 (en) Tubulin inhibitor and process for its preparation
US11319288B2 (en) Method for the preparation of pimavanserin base
US11891375B2 (en) Method for the synthesis of 2,4-dimethylpyrimidin-5-ol, intermediates, and method for the synthesis of Lemborexant using the intermediates
CN115028553B (en) Preparation method of chiral N-Boc/Cbz-cis- (1R, 2S) -cyclohexanediamine
US7329780B2 (en) Method of preparing optically pure phenethylamine derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZHANG, XIANYI;GE, SHAOQING;CHE, DAQING;SIGNING DATES FROM 20120523 TO 20120607;REEL/FRAME:028467/0081

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION